Press Release: Santhera Announces Combination of Two Shareholder Groups

Santhera Pharmaceuticals Holding AG / Santhera Announces Combination of Two Shareholder Groups . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Liestal, Switzerland, January 25, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that it has received from Ernesto Bertarelli, Donata Guichard-Bertarelli, Maria-Iris Bertarelli, (together, the "Bertarelli Group") and Ralf Arnold, Markus Kühnle and Thomas Terhorst (together, the "Iglu Group") the notification that they have combined their respective shareholdings in Santhera to form a new shareholder group.

The above mentioned shareholders have announced that they have formed a new shareholder group with a combined holding in Santhera of 18.84% (1,179,977 shares). Previously, this number of Santhera shares had been owned by the two groups separately, the Bertarelli Group (545,777 shares, 8.71%) and the Iglu Group (634,200 Shares, 10.13%).

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication for Raxone, Santhera has filed a Marketing Authorization Application (MAA) in the European Union and Switzerland. In collaboration with the US National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need. For further information, please visit the Company's website www.santhera.com.

Raxone(R) is a trademark of Santhera Pharmaceuticals.

For further information, contact:

Thomas Meier, PhD, Chief Executive Officer Christoph Rentsch, Chief Financial Officer

Phone +41 61 906 89 64 Phone +41 61 906 89 65

thomas.meier@santhera.com christoph.rentsch@santhera.com

US investor contact US Public Relations contact

Hans Vitzthum, LifeSci Advisors, LLC Deanne Eagle, Planet Communications

Phone +1 212 915 2568 Phone +1 917 837 5866

hans@lifesciadvisors.com deanne@planetcommunications.nyc

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

News Release Shareholders Groups: https://hugin.info/137261/R/2073534/779443.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Santhera Pharmaceuticals Holding AG via Globenewswire

--- End of Message ---

Santhera Pharmaceuticals Holding AG

Hammerstrasse 49 Liestal Switzerland

ISIN: CH0027148649;

http://www.santhera.com (END) Dow Jones Newswires

   January 25, 2017 16:00 ET (21:00 GMT)- - 04 00 PM EST 01-25-17